Reactogenicity of homologous and heterologous prime-boost immunization with BNT162b2 and ChAdOx1-nCoV19: a prospective cohort study

David Hillus; Tatjana Schwarz; Pinkus Tober-Lau; Hana Hastor; Charlotte Thibeault; Stefanie Kasper; Elisa T Helbig; Lena J Lippert; Patricia Tscheak; Marie Luisa Schmidt; Johanna Riege; Andr Solarek; Christof von Kalle; Chantip Dang-Heine; Piotr Kopankiewicz; Norbert Suttorp; Christian Drosten; Harald Bias; Joachim Seybold; - COVIM/EICOV Study Group; Florian Kurth; Victor M Corman; Leif Erik Sander.
Preprint en Inglés | PREPRINT-MEDRXIV | ID: ppmedrxiv-21257334

Documentos relacionados

  1. Reactogenicity and safety of COVID-19 primary immunisation and booster vaccination regimens: a comparative observational cohort study.
  2. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study.
  3. Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study.
  4. Incidence rates of myocarditis and pericarditis within 30 days following homologous and heterologous BNT162b2 vaccinations in individuals 5-40 years of age.
  5. Immunogenicity and efficacy of          heterologous ChAdOx1-BNT162b2 vaccination.
  6. Longitudinal study comparing IgG antibodies induced by heterologous prime-boost COVID-19 vaccine.
  7. Profiling humoral responses to COVID-19 immunization in Kawasaki disease using SARS-CoV-2 variant protein microarrays.
  8. Correlation of adverse effects and antibody responses following homologous and heterologous COVID19 prime-boost vaccinations.
  9. Antibody Response of Heterologous vs Homologous Messenger RNA Vaccine Boosters Against the Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant: Interim Results from the PRIBIVAC Study, a Randomized Clinical Trial.
  10. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial.